Evidence map›Paper›PMID 40561371›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2025

Neuropathic Pain and Distinct CASPR2 Autoantibody IgG Subclasses Drive Neuronal Hyperexcitability.

Margarita Habib, Anna-Lena Wiessler, Patrik Fischer, Michele Niesner, Mareike Selcho, Ligia Abrante, Christian Werner, Annemarie Sodmann, Maximilian Koch, Abdolhossein Zare and 17 more

Abstract read
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Recent advances in autoantibody-mediated pain.Current opinion in supportive and palliative care · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Margarita HabibInstitute for Clinical Neurobiology, University Hospital Wuerzburg, Germany.ORCID 0009-0004-2894-5572
Anna-Lena WiesslerInstitute for Clinical Neurobiology, University Hospital Wuerzburg, Germany.ORCID 0000-0002-2039-3919
Patrik FischerDepartment of Neurology, University Hospital Wuerzburg, Germany.
Michele NiesnerInstitute for Clinical Neurobiology, University Hospital Wuerzburg, Germany.
Mareike SelchoDepartment of Animal Physiology, Institute of Biology, Leipzig University, Germany.
Ligia AbranteInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein Kiel/Lübeck, Germany.
Christian WernerDepartment of Biotechnology and Biophysics, Biocenter, Julius-Maximilians-University Wuerzburg, Germany.ORCID 0000-0003-1281-0919
Annemarie SodmannDepartment of Neurology, University Hospital Wuerzburg, Germany.
Maximilian KochInstitute for Clinical Neurobiology, University Hospital Wuerzburg, Germany.
Abdolhossein ZareInstitute for Clinical Neurobiology, University Hospital Wuerzburg, Germany.
Harald PrüssDepartment of Neurology and Experimental Neurology, Charité Universitätsmedizin Berlin, Germany.ORCID 0000-0002-8283-7976
Justina DargvainieneInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein Kiel/Lübeck, Germany.ORCID 0009-0002-4114-3748
Jan LewerenzDepartment of Neurology, University Hospital Ulm, Germany.ORCID 0000-0002-9272-529X
Robert HandrekaDepartment of Neurology, Medical University Lausitz Carl Thiem, Cottbus, Germany.
Peter KörtvelyessyDepartment of Neurology and Experimental Neurology, Charité Universitätsmedizin Berlin, Germany.ORCID 0000-0003-1262-6169
Dirk ReinholdInstitute for Molecular and Clinical Immunology, University Magdeburg, Germany.
Franziska S ThalerInstitute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians-University Munich, Germany.ORCID 0000-0001-6548-0410
Kalliopi PitarokoiliDepartment of Neurology, St. Josef Hospital, Ruhr-University Bochum, Germany.ORCID 0000-0002-2483-4929
Robert J KittelDepartment of Animal Physiology, Institute of Biology, Leipzig University, Germany.
Michael BrieseInstitute for Clinical Neurobiology, University Hospital Wuerzburg, Germany.
Michael SendtnerInstitute for Clinical Neurobiology, University Hospital Wuerzburg, Germany.
Heike RittnerCenter for Interdisciplinary Pain Medicine, Department of Anesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Wuerzburg, Germany; and.ORCID 0000-0003-4867-0188
Frank LeypoldtInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein Kiel/Lübeck, Germany.ORCID 0000-0002-8972-515X
Claudia SommerDepartment of Neurology, University Hospital Wuerzburg, Germany.ORCID 0000-0002-7064-5002
Robert BlumDepartment of Neurology, University Hospital Wuerzburg, Germany.
Kathrin DopplerDepartment of Neurology, University Hospital Wuerzburg, Germany.ORCID 0000-0003-2883-0009
Carmen VillmannInstitute for Clinical Neurobiology, University Hospital Wuerzburg, Germany.ORCID 0000-0003-1498-6950

Funding

Resource Component: Acquisition, maintenance and distribution of Drosophila stocksP40OD018537 · OD · TRUSTEES OF INDIANA UNIVERSITY · PI Annette L. Parks · 2014 to 2026
$13.5M
NIH HHS P40 OD018537
6 · The paper itself

Abstract

BACKGROUND AND

objectivesPatients with autoantibodies (aAbs) against the contactin-associated protein-like 2 (CASPR2) suffer from a variety of clinical syndromes including neuropathic pain. CASPR2 is an adhesion protein of the neurexin family and part of the voltage-gated potassium channel complex (VGKC complex) in dorsal root ganglia (DRG) neurons. The pathologic mechanisms following the binding of CASPR2 aAbs and their association with pain are only partially understood. CASPR2 aAbs are mainly of the IgG4 subclass; however, previous studies have neglected subclass-dependent effects.

methodsWe investigated 49 subclassified patient serum samples positive for CASPR2 aAbs combining superresolution lattice structural illumination microscopy (SIM

resultsA decrease of CASPR2 expression along the axons after exposure to CASPR2 aAbs was observed for all patient groups except the group without pain and IgG4. Moreover, binding of CASPR2 aAbs from patients with pain increased the distance between CASPR2 and associated potassium channels along DRG axons determined by SIM DISCUSSION: IgG4 aAbs seem to be the major modifier of potassium channel function. The DRG hyperexcitability is primarily due to impaired Kv channel conductance as a consequence of CASPR2 aAb binding. However, additional unidentified signal pathways contribute to this process in patients with neuropathic pain.

Indexed as

AutoantibodiesGanglia, SpinalImmunoglobulin GMembrane ProteinsNerve Tissue ProteinsNeuralgiaNeuronsAdultAgedAnimalsCells, CulturedFemaleHumansMaleMiddle AgedAutoantibodiesCNTNAP2 protein, humanImmunoglobulin GMembrane ProteinsNerve Tissue Proteins

Identifiers

PMID40561371
PMCPMC12202018

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.